Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

ECOG-E1A11
NCT01863550
Cancer - Multiple Myeloma
Kanwarpal Kahlon
Open
Treatment
Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide, Velcade
III
Adult
National

For information about cancer clinical trials at the UC Irvine Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.